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The term 'superantigen' has been introduced to describe a group of microbial antigens that interact with an unusually large proportion of T cells and that differ in some respects from conventional peptide antigens. The recognition of superantigens by the T-cell receptor appears to depend entirely on the variable region of the T-cell receptor 3 chain (V3), instead of the combination of all the T-cell receptor's diverse parts -Vot, Jx, V3, DP, J and N regions -that is required for conventional antigen recognition. As the number of different V3 genes is limited, a superantigen is capable of interacting with a large fraction (2-25 %) of T cells, whereas the frequency of reactive cells for a conventional antigen is usually less than 1 in 1 000. Like peptide antigens, superantigens are presented by class II molecules of the major histocompatibility complex (MHC) but, unlike peptide antigens, they do not attach via the MHC molecule's peptide-binding groove.
At present, two types of superantigen are known. The first type is a protein made by mouse mammary tumor viruses (MMTVs), retroviruses that in infectious form are the causative agents of mammary carcinoma. The second type of superantigen is represented by a growing list of bacterial and mycoplasma proteins, such as staphylococcus or streptococcus toxins. Staphylococcus aureus. produces several enterotoxins -staphylococcal enterotoxins A-E (SEA-SEE) -which cause food poisoning, as well as toxic shock syndrome toxin 1 (TSST-1), which has been implicated in the human toxic shock syndrome. The toxicity of bacterial superantigens is thought to be mediated by their potent T-cell stimulatory activity, which leads to lymphokine release, increased capillary permeability and shock. The two types of superantigen are not structurally related, at least not in their primary protein sequence.
That MMTV superantigens interact directly with MHC class II molecules has so far only been inferred from functional data. Thus, the evidence for the interaction includes the finding that the recognition of MMTV superantigens can be blocked by anti-class II antibodies [1] . Furthermore, mice that are I-E--that is, mice lacking expression of the MHC class II locus I-E -are unable to present most of the MMTV superantigens. It is disappointing that it has not been possible to demonstrate the association between MMTV superantigens and MHC class II by co-immunoprecipitation studies.
The interaction between bacterial toxins and MHC class II proteins has, by contrast, been well characterized. The dissociation constants for the binding of SEA and TSST-1 to MHC class II molecules are estimated to be about 10-7-10-8 M [2, 3] . The interaction with MHC class II molecules appears to involve more than one binding site and varies among the toxins. Thus, Kappler and colleagues deduced from their mutational analysis [4] that SEB has two distinct binding sites for class II molecules. It has also been shown that SEB and TSST-1 interact with different sites on the human class II molecule HLA-DR1, because these two toxins do not compete with each other for binding to HLA-DR. SEA, on the other hand, competes with both SEB and TSST-1, indicating that the toxins bind to separate but overlapping sites on the MHC class II molecule.
Several MHC class II residues that are important for the binding of SEA, SEB and TSST-1 have been mapped. All these residues are on the distal domains of the class II molecule, close to the region involved in T-cell receptor binding, but outside the peptide-binding groove. Overall, the data obtained from mutational studies imply that there is more than one binding site for an individual toxin, and that there are distinct sites for different toxins. These sites appear to involve both the x and 3 chains of MHC class II molecules, and it is possible that the binding results in cross-linking of the two chains.
The recent determination, by X-ray crystallography, of the structures of SEB-DR1 [5] and TSST-1-DR1 [6] complexes has provided direct insights into these issues ( Fig. la-d) . SEB is seen to bind as an intact protein to the -helical region of the DR1 (x chain, outside the conventional peptide-binding groove. SEB thus does not interact directly with the bound antigenic peptide, and no large conformational changes in the DR1-peptide complex seem to be induced by simultaneous binding of SEB. One loop of SEB covers the residues of DR1 recognized by the T-cell receptor in conventional peptide antigen presentation (Fig. la,c) , suggesting an unorthodox mode of interaction between the SEB-DR1 complex and the T-cell receptor.
Although TSST-1 and SEB show only 16% sequence identity, their three-dimensional structures are very similar. TSST-1 does, however, differ in sequence from SEB at residues involved in binding to DR1, suggesting that the two toxins interact with class II differently. This is demonstrated by the respective crystal structures of their complexes with DR1. SEB contacts DR1 at two sites, exclusively on the DR1 ot chain, primarily off one edge of © Current Biology 1995, Vol 5 No 3 235 the peptide-binding groove (Fig. la,c) . The TSST-1 binding site, on the other hand, extends over almost half of the peptide-binding site, so that TSST-1 contacts the helix of the DR1 a chain, the bound peptide and part of the ct helix of the DR1 13 chain (Fig. lb,d ). This suggests that TSST-1 binding is likely to be peptide-dependent.
Furthermore, it is likely that the recognition of TSST-1-DR1 by the T-cell receptor is very different from that of SEB-DRi or peptide-DR1.
Although no crystal structure of a T-cell receptor has yet been determined, several models of its three-dimensional configuration have been proposed. The Davis and Bjorkman model [7] predicts that the T-cell receptor folds, like immunoglobulins, into three 'complementaritydetermining regions' (CDR1-3) that bind to the peptide-MHC molecule complex. CDR1 and CDR2 interact with the MHC molecule, and CDR3, formed by the VolJa and V3D3J3 junction, contacts the peptide in the groove of the MHC molecule. The region of the T-cell receptor that interacts with a superantigen has been shown to be a hypervariable loop, HV4, in the V3 domain between strands D and E, corresponding to residues 67-77 of the human V chain, which is predicted to form a solvent-exposed face located on one side of the antigen-binding face [8] .
Structural models for T-cell receptor interaction with a superantigen have been proposed based on mutational analyses and the three-dimensional configurations of SEB, TSST-1 and the SEB-DR1 complex [5, 9, 10] . Direct binding studies of many toxins to class II molecules suggest that different bacterial toxins contact distinct regions on the MHC molecule, even though they all interact directly with the T-cell receptor V chain, implying that there are many distinct modes of interaction between T-cell receptor, superantigen and class II molecule. The distinct modes of toxin binding to DR1 revealed by the crystallographic studies indicates that the T-cell receptor may be oriented differently in complexes with different superantigens. In addition, the fact that TSST-1 contacts the peptide in the peptide-binding groove suggests that T-cell activation by certain superantigens may be directed by the peptide antigen.
Although very little is known about the recognition of MMTV superantigens by the T-cell receptor, the residues on the V3 chain involved in binding viral superantigens appear to be on the same solvent-exposed face as those -generally different -residues that are involved in binding the bacterial toxins. Mutational analysis of the interaction between V and the Mtv-7 superantigen showed that the critical amino acids are within the HV4 loop of V3 and an adjacent 3 strand leading up to the CDR1 loop [11] . Thus, all the available data so far suggest that both bacterial and viral superantigens bind to a solvent-exposed face on the lateral side of the T-cell receptor V3 chain, which is distinct from the conventional peptide recognition site.
The recent elucidation of the crystal structures of SEB-DR1 and TSST-1-DR1 complexes has, therefore, provided a clear picture of the diversity in of interactions between toxins and MHC class II molecules [5, 6] . The interesting and surprising findings of the very different binding modes of these two toxins suggest different ways of T-cell receptor recognition of superantigens.
